{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:20:45Z","timestamp":1777620045057,"version":"3.51.4"},"reference-count":25,"publisher":"American Diabetes Association","issue":"10","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":2902,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,10,1]]},"abstract":"<jats:p>Statin and angiotensin II type 1 receptor blocker therapy improves endothelial dysfunction using distinct mechanisms. We evaluated simultaneous vascular and metabolic responses to pravastatin and valsartan therapy, alone or in combination, in hypercholesterolemic patients. Forty-eight hypercholesterolemic patients (23 had metabolic syndrome) were given pravastatin 40 mg and placebo, pravastatin 40 mg and valsartan 160 mg, or valsartan 160 mg and placebo daily during each 2-month treatment period in a randomized, single-blind, placebo-controlled, crossover trial with three treatment arms and two washout periods (each 2 months). Brachial artery flow-mediated dilation and C-reactive protein improved to a greater extent with combined therapy compared with either monotherapy. Importantly, we also observed simultaneous improvement in metabolic phenotypes, with all three treatments causing increased plasma adiponectin levels, reduced fasting insulin levels, and increased insulin sensitivity relative to baseline measurements. For the first time in a statin combination trial, pravastatin combined with valsartan therapy increased plasma adiponectin, lowered fasting insulin levels, and improved insulin sensitivity in an additive manner when compared with monotherapy alone. In contrast to other statins, hydrophilic pavastatin may be combined with other drugs to safely reach lipid target levels while simultaneously improving the metabolic and cardiovascular phenotype of patients at high risk.<\/jats:p>","DOI":"10.2337\/db13-0566","type":"journal-article","created":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T04:26:04Z","timestamp":1374121564000},"page":"3547-3552","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":25,"title":["Combination Pravastatin and Valsartan Treatment Has Additive Beneficial Effects to Simultaneously Improve Both Metabolic and Cardiovascular Phenotypes Beyond That of Monotherapy With Either Drug in Patients With Primary Hypercholesterolemia"],"prefix":"10.2337","volume":"62","clinical-trial-number":[{"clinical-trial-number":"nct01004237","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Kwang Kon","family":"Koh","sequence":"first","affiliation":[{"name":"Cardiology, Gachon University Gil Medical Center, Incheon, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanul","family":"Choi","sequence":"additional","affiliation":[{"name":"Cardiology, Gachon University Gil Medical Center, Incheon, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghee","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Statistics, University of Seoul, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Hwan","family":"Han","sequence":"additional","affiliation":[{"name":"Cardiology, Gachon University Gil Medical Center, Incheon, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyounghoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Cardiology, Gachon University Gil Medical Center, Incheon, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pyung Chun","family":"Oh","sequence":"additional","affiliation":[{"name":"Cardiology, Gachon University Gil Medical Center, Incheon, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Sakuma","sequence":"additional","affiliation":[{"name":"Cardiovascular Medicine, Hokko Memorial Clinic, Sapporo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eak Kyun","family":"Shin","sequence":"additional","affiliation":[{"name":"Cardiology, Gachon University Gil Medical Center, Incheon, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Quon","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2013,9,17]]},"reference":[{"key":"2022031211351950200_B1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0008-6363(00)00146-2","article-title":"Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability","volume":"47","author":"Koh","year":"2000","journal-title":"Cardiovasc Res"},{"key":"2022031211351950200_B2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.atherosclerosis.2009.09.007","article-title":"Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction","volume":"209","author":"Koh","year":"2010","journal-title":"Atherosclerosis"},{"key":"2022031211351950200_B3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/MOL.0b013e328012b627","article-title":"Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction","volume":"18","author":"Han","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"2022031211351950200_B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2010.10.036","article-title":"Differential metabolic effects of distinct statins","volume":"215","author":"Koh","year":"2011","journal-title":"Atherosclerosis"},{"key":"2022031211351950200_B5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.HYP.0000125726.92964.ab","article-title":"Adverse prognostic significance of new diabetes in treated hypertensive subjects","volume":"43","author":"Verdecchia","year":"2004","journal-title":"Hypertension"},{"key":"2022031211351950200_B6","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.2337\/dc12-0002","article-title":"Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults","volume":"35","author":"Campbell","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031211351950200_B7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2337\/dc07-2199","article-title":"Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients","volume":"31","author":"Koh","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031211351950200_B8","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jacc.2009.10.053","article-title":"Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients","volume":"55","author":"Koh","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2022031211351950200_B9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2008.09.021","article-title":"Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients","volume":"204","author":"Koh","year":"2009","journal-title":"Atherosclerosis"},{"key":"2022031211351950200_B10","doi-asserted-by":"crossref","first-page":"f2610","DOI":"10.1136\/bmj.f2610","article-title":"Risk of incident diabetes among patients treated with statins: population based study","volume":"346","author":"Carter","year":"2013","journal-title":"BMJ"},{"key":"2022031211351950200_B11","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","author":"National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","year":"2002","journal-title":"Circulation"},{"key":"2022031211351950200_B12","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1161\/01.CIR.0000143085.86697.13","article-title":"Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients","volume":"110","author":"Koh","year":"2004","journal-title":"Circulation"},{"key":"2022031211351950200_B13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/01.HYP.0000133310.42762.25","article-title":"Simvastatin combined with ramipril treatment in hypercholesterolemic patients","volume":"44","author":"Koh","year":"2004","journal-title":"Hypertension"},{"key":"2022031211351950200_B14","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jacc.2005.02.052","article-title":"Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia","volume":"45","author":"Koh","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2022031211351950200_B15","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1210\/jcem.85.7.6661","article-title":"Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans","volume":"85","author":"Katz","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031211351950200_B16","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.2337\/diabetes.54.7.1914","article-title":"Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model","volume":"54","author":"Chen","year":"2005","journal-title":"Diabetes"},{"key":"2022031211351950200_B17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ijcard.2011.11.028","article-title":"Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients","volume":"166","author":"Koh","year":"2013","journal-title":"Int J Cardiol"},{"key":"2022031211351950200_B18","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/01.CIR.103.3.357","article-title":"Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study","volume":"103","author":"Freeman","year":"2001","journal-title":"Circulation"},{"key":"2022031211351950200_B19","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1185\/030079908X292029","article-title":"The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"24","author":"Coleman","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2022031211351950200_B20","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"2022031211351950200_B21","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.jacc.2010.10.047","article-title":"Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials","volume":"57","author":"Waters","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2022031211351950200_B22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacc.2012.09.042","article-title":"Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes","volume":"61","author":"Waters","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2022031211351950200_B23","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jacc.2004.04.050","article-title":"Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model","volume":"44","author":"Yu","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2022031211351950200_B24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2007.02.013","article-title":"Effect of pravastatin on the development of diabetes and adiponectin production","volume":"196","author":"Takagi","year":"2008","journal-title":"Atherosclerosis"},{"key":"2022031211351950200_B25"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/62\/10\/3547\/570930\/3547.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/62\/10\/3547\/570930\/3547.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:36:46Z","timestamp":1667407006000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/62\/10\/3547\/17589\/Combination-Pravastatin-and-Valsartan-Treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,17]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,9,17]]},"published-print":{"date-parts":[[2013,10,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db13-0566","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,17]]}}}